Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy.
about
Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles.High Perforin-Positive Cardiac Cell Infiltration and Male Sex Predict Adverse Long-Term Mortality in Patients With Inflammatory Cardiomyopathy.Inflammation in Heart Failure: known knowns and unknown unknowns.Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature.High incidence of cardiac dysfunction and response to antiviral treatment in patients with chronic hepatitis C virus infection.Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach.Spontaneous activation of a MAVS-dependent antiviral signaling pathway determines high basal interferon-β expression in cardiac myocytes.[Inflammatory cardiomyopathy and myocarditis].Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy.Age-Associated Changes in Estrogen Receptor Ratios Correlate with Increased Female Susceptibility to Coxsackievirus B3-Induced Myocarditis.Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy.T1 and T2 mapping cardiovascular magnetic resonance imaging techniques reveal unapparent myocardial injury in patients with myocarditis.Cardiovascular Involvement in Chronic Hepatitis C Virus Infections – Insight from Novel Antiviral Therapies.Treatment options in myocarditis and inflammatory cardiomyopathy : Focus on i. v. immunoglobulinsCCR5del32 genotype in human enteroviral cardiomyopathy leads to spontaneous virus clearance and improved outcome compared to wildtype CCR5
P2860
Q33712962-D0EC23AB-C57B-45D3-AD7B-5FC4A0119446Q38597919-36659D26-13F3-4502-B6D5-8C44049EABD7Q38692564-6FD002A1-0174-4C87-8501-9FAF4EA4F91AQ38810914-8B2F79C9-71AF-479B-92B4-07B666169AD7Q38943071-2ABD30EE-421D-4C9A-A6A9-65A8B9D033F8Q39426840-9F2DC18C-81FF-44B6-9123-2E520D5F73A9Q40077630-CA1DE7AA-3603-4ED8-8427-06FF3C15C53CQ40224028-27AF972D-C058-4A7A-B826-BB8662748D67Q40696451-C09133D3-F59E-42DD-B726-4AA9CE27DBF3Q47158045-39DED009-0F6A-49F7-9F23-58F425D05625Q52660853-0E5BDF89-89A3-4223-BB5C-F96D5FB37988Q53798523-4B57D3D2-D99D-42E1-B0D1-566CBAE37124Q55284802-44520C06-C7AF-45EE-9001-DC464B40C0CFQ56924750-1E830659-E4B9-4963-86A9-49F166AC6B6CQ58765254-961EDB4A-0FBE-454B-BFEE-6821BEAF5B88
P2860
Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Betaferon in chronic viral car ...... chronic viral cardiomyopathy.
@en
type
label
Betaferon in chronic viral car ...... chronic viral cardiomyopathy.
@en
prefLabel
Betaferon in chronic viral car ...... chronic viral cardiomyopathy.
@en
P2093
P2860
P1476
Betaferon in chronic viral car ...... chronic viral cardiomyopathy.
@en
P2093
Cornelia Piper
Felicitas Escher
Finn Waagstein
Georg Groetzbach
Harald Siedentop
Heinz-Peter Schultheiss
Joachim-Friedrich Kapp
Karl Wegscheider
Matthias Pauschinger
Olaf Sowade
P2860
P2888
P304
P356
10.1007/S00392-016-0986-9
P577
2016-04-25T00:00:00Z